Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma · line 2 · Carfilzomib + Rituximab + Dexamethasone (CaRD) × 6 cycles — for CXCR4-WHIM-mutated WM (BTKi-resistant subset)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-CARFILZOMIB-WM |
| ID | IND-WM-2L-CARFILZOMIB-CXCR4MUT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-WM |
| Sources | SRC-ESMO-WM-2024 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for r/r WM. Particularly preferred for CXCR4-WHIM-mutated subset (BTKi-resistant) and bortezomib-intolerant patients (neuropathy). UA-accessible off-label via MM supply route.
Used By
Algorithms
ALGO-WM-2L- ALGO-WM-2L
Red flag
RF-WM-CXCR4-WHIM-MUTANT- CXCR4 WHIM-like nonsense or frameshift mutation in the C-terminal regulatory domain (e.g....